NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug
17 févr. 2023 08h00 HE
|
NurExone
TORONTO and HAIFA, Israel, Feb. 17, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V), a biopharmaceutical company developing biologically-guided exosome therapy...